PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
DAC vs. OLMA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DAC and OLMA is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

DAC vs. OLMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Danaos Corporation (DAC) and Olema Pharmaceuticals, Inc. (OLMA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-7.05%
-60.45%
DAC
OLMA

Key characteristics

Sharpe Ratio

DAC:

0.20

OLMA:

-0.63

Sortino Ratio

DAC:

0.46

OLMA:

-0.68

Omega Ratio

DAC:

1.06

OLMA:

0.92

Calmar Ratio

DAC:

0.06

OLMA:

-0.55

Martin Ratio

DAC:

0.46

OLMA:

-1.44

Ulcer Index

DAC:

10.65%

OLMA:

34.51%

Daily Std Dev

DAC:

24.10%

OLMA:

79.46%

Max Drawdown

DAC:

-99.42%

OLMA:

-96.26%

Current Drawdown

DAC:

-81.19%

OLMA:

-89.61%

Fundamentals

Market Cap

DAC:

$1.50B

OLMA:

$420.22M

EPS

DAC:

$28.89

OLMA:

-$2.44

Total Revenue (TTM)

DAC:

$751.40M

OLMA:

$0.00

Gross Profit (TTM)

DAC:

$500.14M

OLMA:

-$182.00K

EBITDA (TTM)

DAC:

$520.19M

OLMA:

-$105.21M

Returns By Period

In the year-to-date period, DAC achieves a -3.26% return, which is significantly lower than OLMA's -2.92% return.


DAC

YTD

-3.26%

1M

1.14%

6M

-7.04%

1Y

6.56%

5Y*

60.42%

10Y*

2.24%

OLMA

YTD

-2.92%

1M

-3.25%

6M

-60.45%

1Y

-49.51%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DAC vs. OLMA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAC
The Risk-Adjusted Performance Rank of DAC is 4848
Overall Rank
The Sharpe Ratio Rank of DAC is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of DAC is 4444
Sortino Ratio Rank
The Omega Ratio Rank of DAC is 4343
Omega Ratio Rank
The Calmar Ratio Rank of DAC is 4848
Calmar Ratio Rank
The Martin Ratio Rank of DAC is 5151
Martin Ratio Rank

OLMA
The Risk-Adjusted Performance Rank of OLMA is 1414
Overall Rank
The Sharpe Ratio Rank of OLMA is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of OLMA is 1616
Sortino Ratio Rank
The Omega Ratio Rank of OLMA is 1717
Omega Ratio Rank
The Calmar Ratio Rank of OLMA is 1515
Calmar Ratio Rank
The Martin Ratio Rank of OLMA is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DAC vs. OLMA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Danaos Corporation (DAC) and Olema Pharmaceuticals, Inc. (OLMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for DAC, currently valued at 0.20, compared to the broader market-2.000.002.004.000.20-0.63
The chart of Sortino ratio for DAC, currently valued at 0.46, compared to the broader market-4.00-2.000.002.004.000.46-0.68
The chart of Omega ratio for DAC, currently valued at 1.06, compared to the broader market0.501.001.502.001.060.92
The chart of Calmar ratio for DAC, currently valued at 0.17, compared to the broader market0.002.004.006.000.17-0.55
The chart of Martin ratio for DAC, currently valued at 0.46, compared to the broader market-10.000.0010.0020.000.46-1.44
DAC
OLMA

The current DAC Sharpe Ratio is 0.20, which is higher than the OLMA Sharpe Ratio of -0.63. The chart below compares the historical Sharpe Ratios of DAC and OLMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
0.20
-0.63
DAC
OLMA

Dividends

DAC vs. OLMA - Dividend Comparison

DAC's dividend yield for the trailing twelve months is around 4.20%, while OLMA has not paid dividends to shareholders.


TTM2024202320222021
DAC
Danaos Corporation
4.20%4.06%4.12%5.70%2.01%
OLMA
Olema Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%

Drawdowns

DAC vs. OLMA - Drawdown Comparison

The maximum DAC drawdown since its inception was -99.42%, roughly equal to the maximum OLMA drawdown of -96.26%. Use the drawdown chart below to compare losses from any high point for DAC and OLMA. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-18.16%
-89.61%
DAC
OLMA

Volatility

DAC vs. OLMA - Volatility Comparison

The current volatility for Danaos Corporation (DAC) is 7.92%, while Olema Pharmaceuticals, Inc. (OLMA) has a volatility of 27.83%. This indicates that DAC experiences smaller price fluctuations and is considered to be less risky than OLMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
7.92%
27.83%
DAC
OLMA

Financials

DAC vs. OLMA - Financials Comparison

This section allows you to compare key financial metrics between Danaos Corporation and Olema Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab